Organogenesis Holdings Inc. (NASDAQ: ORGO) is a regenerative medicine company focused on the development, manufacture and commercialization of advanced tissue repair solutions. The company operates two principal business segments—Advanced Wound Care and Surgical Orthobiologics—offering a range of human cellular and tissue‐based products designed to support the body’s natural healing processes. Organogenesis’ therapies address chronic and acute wounds as well as a variety of surgical soft tissue repair needs.
In its Advanced Wound Care segment, Organogenesis markets living and non‐living skin substitutes and placental tissue products, including offerings that target diabetic foot ulcers, venous leg ulcers and other difficult‐to‐treat wounds. Within the Surgical Orthobiologics business, the company provides demineralized bone matrices, amniotic membrane grafts and other matrix products engineered to support tendon, ligament, nerve and soft tissue repair. These products are distributed primarily through a direct sales force across hospitals, wound care centers and specialty clinics in the United States, with select partnerships extending distribution into international markets.
Founded in 1985 and headquartered in Canton, Massachusetts, Organogenesis has grown through internal innovation, strategic acquisitions and collaborative research agreements with leading academic and clinical institutions. The company maintains FDA‐registered manufacturing facilities in the U.S. and holds an extensive intellectual property portfolio covering its cell and tissue technologies. Over its history, Organogenesis has expanded its product pipeline and production capacity to meet evolving clinical needs.
Organogenesis is led by an executive management team and board of directors with deep expertise in biotechnology, medical devices and healthcare commercialization. Leadership priorities include scaling commercial operations, advancing clinical development programs and expanding global access to regenerative therapies. The company continues to invest in research and development to bolster its pipeline and drive sustainable long-term growth in the regenerative medicine market.
AI Generated. May Contain Errors.